TICKERNERD
Menu
KYNBHealthcare · Biotechnology

KYNB Stock Forecast: Kyntra Bio, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$7.97
−0.06% on the day

The 3 Wall Street analysts covering Kyntra Bio, Inc. hold a median 12-month price target of $39 — +389.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$32.3M
Ticker Nerd rank
45 / 100
Median analyst target
$39
Analysts covering
3
Revenue−$1.5M−209.3% y/y
Operating income−$17.6M
Net income$12.0M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.1%
1M
+12.7%
YTD
−9.2%
1Y
−35.9%
From 52W high
−35.9%
From 52W low
+23.4%
$6
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KYNB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kyntra Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
45 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
94
Size
85
Revisions
58
Volatility
45
Quality
44
Momentum
43
Growth
29
Accruals
28
Value
18

Issuance (94): The share count has been shrinking and the company is not leaning on new borrowing.

Value (18): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KYNB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KYNB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26KYNBHigh $43Median $39Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $35Median $39High $43

The green dot is the last close — the median target sits +389.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
1 Sept 2026HC Wainwright & Co.ReiteratesBuy$43
7 July 2026OppenheimerInitiatesOutperform$35
7 July 2026OppenheimerInitiatesOutperform—
9 June 2026Rodman & RenshawInitiatesBuy—
24 Sept 2025HC Wainwright & Co.ReiteratesBuy—
7 Aug 2025HC Wainwright & Co.MaintainsBuy—
13 May 2025HC Wainwright & Co.ReiteratesBuy$10
18 Mar 2025HC Wainwright & Co.ReiteratesBuy$10
20 Feb 2025HC Wainwright & Co.ReiteratesBuy$10
8 Aug 2023B of A SecuritiesDowngradeUnderperform$4.00 → $2.00
27 June 2023Goldman SachsMaintainsSell$16 → $2.00
27 June 2023Raymond JamesDowngradeMarket Perform—
26 June 2023B of A SecuritiesDowngradeNeutral$29 → $4.00
26 June 2023Raymond JamesDowngradeMarket Perform—
26 June 2023StifelDowngradeHold$28 → $11
26 June 2023William BlairDowngradeMarket Perform—
2 June 2023StifelUpgradeBuy—
28 Feb 2023Cowen & Co.MaintainsMarket Perform$15 → $25
23 Feb 2023Goldman SachsMaintainsSell$9.00 → $16
21 Feb 2023Goldman SachsMaintainsSell$9.00 → $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KYNB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KYNB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Kyntra Bio, Inc. returned −35.9% against +17.5% for the S&P 500, dividends included.

KYNB vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26KYNBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KYNB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Kyntra Bio, Inc. (KYNB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 72% of US stocks

Price / sales
7.0×

Cheaper than 18% of US stocks

Price / book
−3.9×

Cheaper than 96% of US stocks

EV / EBITDA
0.7×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
−139.4%

Higher than 1% of US stocks

Earnings growth (YoY)
−209.3%

Higher than 1% of US stocks

Gross margin
100.1%

Higher than 99% of US stocks

Operating margin
1191.5%

Higher than 99% of US stocks

Net margin
3968.6%

Higher than 99% of US stocks

Returns & dividend
Return on equity
4099.5%

Higher than 99% of US stocks

Return on assets
−22.5%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kyntra Bio, Inc. (KYNB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kyntra Bio, Inc. has a market value of $32.3M and an enterprise value of −$37.0M.

  • Revenue in the twelve months to 30 June 2026: $4.6M. The latest quarter shrank 139.4% year on year.

  • Net income over the same four quarters: $183.2M, a 3967.8% net margin.

  • Diluted earnings per share, trailing twelve months: $45.30.

  • Free cash flow in the twelve months to 30 June 2026: −$38.1M.

  • Shares outstanding: 4.0M.

  • Trailing P/E: 0.2×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Kyntra Bio, Inc. employs 34 people — $136K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

KYNB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KYNBKyntra Bio, Inc.$32.3M
45
ALGSAligos Therapeutics, Inc.$32.3M
74
CNTXContext Therapeutics, Inc.$32.2M
28
NXTCNextCure, Inc.$32.0M
79
LGVNLongeveron, Inc.$32.9M
31
BYSIBeyondSpring, Inc.$31.4M
20
BCTXBriaCell Therapeutics Corp.$31.3M
7

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kyntra Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KYNB news & analysis

Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 2 Sept 2026neutral

Kyntra Bio (Nasdaq: KYNB) announced that its management will attend and present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York, NY. The company made the announcement on September 2, 2026.

Why it matters — A KYNB watcher would care because the company's management presentation at a major investment conference provides an opportunity for investors to hear directly from leadership about the company.

Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation

GlobeNewsWire · 31 Aug 2026positive

Kyntra Bio announced it signed an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, L.P. The amendment materially reduces its payment obligations under the agreement in exchange for an accelerated upfront payment.

Why it matters — A significant reduction in royalty financing obligations could improve Kyntra Bio's balance sheet and future cash flow profile.

Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published the transcript of Kyntra Bio, Inc.'s (KYNB) Q2 2026 earnings call. The item consists solely of the earnings call transcript headline and source, with no additional details from the call included.

Why it matters — A KYNB watcher would care because a published earnings call transcript provides management's commentary on the company's second-quarter 2026 results.

Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 13 Aug 2026negative

Kyntra Bio (KYNB) reported a second-quarter loss of $4.68 per share, wider than the Zacks Consensus Estimate of a $3.18 loss and larger than the $3.38 per-share loss from the same quarter a year ago. Revenue came in below estimates.

Why it matters — KYNB watchers would care because the company's quarterly loss significantly exceeded analyst expectations and worsened year over year, indicating weaker-than-anticipated financial performance.

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 13 Aug 2026neutral

Kyntra Bio (Nasdaq: KYNB) reported its financial results for the second quarter of 2026 and provided an update on the company's recent developments. The announcement was made on August 13, 2026, via GlobeNewswire.

Why it matters — KYNB watchers would care because the report details the company's Q2 2026 financial performance and outlines its latest business developments.

FAQ

Frequently asked questions about KYNB stock

What is the KYNB stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Kyntra Bio, Inc. have a median 12-month price target of $39, with estimates ranging from $35 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KYNB stock a buy right now?

Of the 3 analysts covering Kyntra Bio, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kyntra Bio, Inc. 45 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KYNB?

As at 12 Sept 2026, Kyntra Bio, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (94 of 100).

Will KYNB stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +389.3% from the last close, and Ticker Nerd's factor model ranks Kyntra Bio, Inc. 45 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KYNB stock forecast for 2030?

No analyst covering Kyntra Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYNB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $43 over the next 12 months.

How has KYNB stock performed over the past year?

Kyntra Bio, Inc. returned -35.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kyntra Bio, Inc. do?

Kyntra Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for serious unmet medical needs.

What is the latest news on KYNB?

The most recent item we track (GlobeNewsWire, 2 Sept 2026): "Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference". Kyntra Bio (Nasdaq: KYNB) announced that its management will attend and present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York, NY. The company made the announcement on September 2, 2026.

Company

About Kyntra Bio, Inc.

Kyntra Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for serious unmet medical needs. Kyntra Bio’s current pipeline centers on oncology and anemia, including FG-3246, an antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer and other cancers, as well as roxadustat, a small-molecule HIF-PH inhibitor being developed for anemia-related indications. The company also works in fibrotic disease biology through its research on hypoxia-inducible factor and connective tissue growth factor pathways. Headquartered in San Francisco, California, Kyntra Bio serves the broader life sciences market by advancing treatments intended for patients with cancer, blood disorders, and other severe diseases.

CEO Mr. Thane Wettig · 34 employees · United States · https://www.kyntrabio.com